ArticleArchives of medical sciences. Atherosclerotic diseases2025
Cortisol as a factor contributing to the development of non-alcoholic fatty liver disease in severely obese patients: a single-center prospective study.
Article in Archives of medical sciences. Atherosclerotic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nonalcoholic fatty liver disease (NAFLD) is known to have high prevalence in obese patients, and has been found to be associated with the metabolic syndrome (MetS). This study aimed to investigate possible correlations of NAFLD with hypothalamic-pituitary-adrenal (HPA) axis activity and expression levels of hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptors) a (NR3C1a) and b (NR3C1b) in the liver, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Material and methods: In this single-center study, 34 severely obese patients (BMI > 40 kg/m Results: The expression of the visceral adipose tissue HSD11B1 (VAT HSD11B1) was significantly higher in the groups of patients with NAFLD (NAFLD+) or NASH (NASH+), compared with those without (NAFLD-, NASH-). The expression of NR3C1a in the liver (LNR3C1a) was significantly lower in the NAFLD+ group compared with the NAFLD- group. In the NAFLD group, the expression of HSD11B1 in the liver (LHSD11B1) exhibited a negative correlation with LNR3C1a, whereas no association was found in the NAFLD+ group. Conclusions: The activity of the HPA axis, and tissue and systemic cortisol levels, contribute to MetS development. There are similarities between MetS and NAFLD concerning their pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.